Verfahren und Anwendung zur Beurteilung der Schwere einer chronisch obstruktiven Lungenerkrankung (COPD)

Details

Veröffentlichungs-Nr.

EP2647995

Aktenzeichen

EP12162884

Anmeldetag

2. April 2012

Veröffentlichung

18. Februar 2015

Erteilung

18. Februar 2015

Rechtsraum

EP

IPC

G01N33/68

Abstract

The invention provides a method of assessing the severity of obstructive pulmonary disease in a subject as well as a method of stratifying a subject for obstructive pulmonary disease therapy. Assessing the severity of obstructive pulmonary disease comprises detecting the amount of pro-pulmonary surfactant-associated protein B (proSP-B), or an effective portion thereof, in a sample from a subject, and comparing the amount of proSP-B in the sample to a threshold value. An increased amount of proSP-B, or the portion thereof indicates an increase in severity of obstructive pulmonary disease. Stratifying a subject for obstructive pulmonary disease therapy comprises detecting the amount of proSP-B, of NT-pro BNP, of troponin T, and of C-reactive protein (CRP) in a sample from the subject, and comparing the amount of proSP-B, NT-pro BNP, troponin T, and CRP in the sample to a threshold value. Very high levels of each of NT-pro BNP and troponin T, and high levels of proSP-B and CRP in the sample relative to the corresponding threshold value, indicate that the subject is in need of at least one of intense surveillance and antibiotic therapy.

Anmelder

Firmen

Roche Diagnostics GmbH
F. Hoffmann-La Roche AG

Land

🇩🇪 Deutschland

Fachgebiete